Protease inhibitor-based HAART, HDL, and CHD-risk in HIV-infected patients

Atherosclerosis

Volumn 184, Issue 1, 2006, Pages 72-77

  Asztalos, Bela F ^a   Schaefer, Ernst J ^a   Horvath, Katalin V ^a   Cox, Caitlin E ^a   Skinner, Sally ^b   Gerrior, Jul ^b   Gorbach, Sherwood L ^b   Wanke, Christine ^b  

^a TUFTS UNIVERSITY   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CHD risk; HAART; HDL particles; HIV infection; Lipoproteins

Indexed keywords

ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDINAVIR; LAMIVUDINE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; TRIACYLGLYCEROL; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFECT; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISCHEMIC HEART DISEASE; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; DISEASE PROGRESSION; FEMALE; HIV; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROTEASE INHIBITORS; RISK FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 28344452695     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2005.04.013     Document Type: Article

References (28)

1. D. Periard, A. Telenti, and P. Sudre Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors Circulation 100 1999 700 705
2. K. Mulligan, C. Grunfeld, and V.W. Tai Hyperinsulinemia and insulin resistance induced by protease inhibitors independent of changes in body composition in patients with HIV infection J Aids 23 2000 35 43
3. K.L. Echevarria, T.C. Hardin, and J.A. Smith Hyperlipidemia associated with protease inhibitor therapy Ann Pharmacother 33 1999 859 863
4. J.Q. Purnell, A. Zambon, and R.H. Knopp Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects Aids 14 2000 51 57
5. B.M. Sadler, P.J. Piliero, S.L. Preston, P.P. Lloyd, Y. Lou, and D.S. Stein Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers Aids 15 2001 1009 1018
6. M.A. Noor, J.C. Lo, and K. Mulligan Metabolic effects of indinavir in healthy HIV-seronegativ men Aids 15 2001 H11 H18
7. B.T. Roge, T.L. Katzenstein, and J. Gerstof Comparison of p-triglyceride levels among patients with human immunodeficiency virus on randomized treatment with ritonavir, indinavir, or ritonavir/saquinavir Scan J Infect Dis 33 2001 306 311
8. K.E. Yarasheski, P. Tebas, and C. Sigmund Insulin resistance in HIV protease inhibitor-associated diabetes J Aids 21 1999 209 216
9. K.M. Anderson, W.P. Castelli, and D. Levy Cholesterol and mortality. Thirty years follow-up from the Framingham heart study JAMA 257 1987 2176 2180
10. Report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. Arch Intern Med 1988; 148:36-69.
11. Executive summary on the third report of the National Cholesterol Education Program (NCEP). Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA 2001; 285:2486-2497.
12. D.J. Gordon, J. Knoke, J.L. Probstfield, R. Superko, and H.A. Tyroler High density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: the lipid research clinics coronary primary prevention trial Circulation 74 1986 1217 1225
13. H.O. Mowri, W. Patsch, L.C. Smith, A.M. Gotto, and J.R. Patsch Different reactivities of high density lipoprotein2 subfractions with hepatic lipase J Lipid Res 33 1992 1269 1279
14. G.R. Castro, and C.J. Fielding Early incorporation of cell-derived cholesterol into pre-β-migrating high-density lipoprotein Biochemistry 27 1988 25 29
15. T. Miida, M. Kawano, C.J. Fielding, and P.E. Fielding Regulation of the concentration of pre-β high-density lipoprotein in normal plasma by cell membranes and lecithin-cholesterol acyltransferase activity Biochemistry 31 1992 11112 11117
16. B.F. Asztalos, C.H. Sloop, L. Wong, and P.S. Roheim Two-dimensional electrophoresis of plasma lipoproteins: recognition of new apo-A-I containing subpopulations Biochim Biophys Acta 1169 1993 291 300
17. B.F. Asztalos, M. Lefevre, and T.A. Foster Normolipidemic subjects with low HDL cholesterol levels have altered HDL subpopulations Arterioscler Thromb Vasc Biol 17 1997 1885 1893
18. B.F. Asztalos, P.S. Roheim, and R.L. Milani Distribution of ApoA-I containing HDL subpopulations in patients with coronary heart disease Arterioscler Thromb Vasc Biol 20 2000 2670 2676
19. B.F. Asztalos, M. Batista, and K.V. Horvath Change in alpha-1 HDL concentration predicts progression in coronary stenosis Arterioscler Thromb Vasc Biol 23 2003 847 852
20. B.F. Asztalos, L.A. Cupples, and S. Demissie High-density subpopulation profile and heart disease prevalence in male participants of the Framingham offspring study Arterioscler Thromb Vasc Biol 24 2004 2181 2187
21. Jacobson DL, Knox T, Speigelman D, Skinner S, Gorbach SL, Wanke CA. Prevalence and evolution of fat atrophy and fat deposition in a cohort of HIV-infected men and women, Clin Infect Dis, in press.
22. C. Grunfeld, D.P. Kotler, and J.K. Shigenaga Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome Am J Med 90 1991 154 162
23. K.R. Feingold, R.M. Krauss, M. Pang, DoerrlerW, P. Jensen, and C. Grunfeld The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence low density lipoprotein subclass pattern B J Clin Endocrinol Metab 76 1993 1423 1427
24. D.N. Reeds, B. Mittendorfer, B.W. Patterson, W.G. Powderly, K.E. Yarasheski, and S. Klein Alterations in lipid kinetics in men with HIV-dyslipidemia Am J Physiol 285 2003 490 497
25. T. Miida, Y. Nakamura, and K. Inano Pre-beta-1 high-density lipoprotein increases in coronary artery disease Clin Chem 42 1996 1992 1995
26. M. van der Valk, J.J. Kastelein, and R.L. Murphy Atlantic Study Team. Nevirapine-containing anti-retroviral therapy in HIV-1 infected patient results in an anti-atherogenic lipid profile Aids 15 18 2001 2407 2414
27. B.F. Asztalos, K.V. Horvath, J.R. McNamara, P.S. Roheim, J.J. Rubinstein, and E.J. Schaefer Comparing the effects of five different statins on the HDL subpopulation profile of coronary heart disease patients Atherosclerosis 164 2002 361 369
28. M.E. Brousseau, E.J. Schaefer, and M.L. Wolfe Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol N Engl J Med 350 15 2004 1505 1515